Deregulation of mitochondrial ATPsyn-β in acute myeloid leukemia cells and with increased drug resistance

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Xiao, Xiang ^a   Yang, Jingke ^a   Li, Ruijuan ^a   Liu, Sufang ^a   Xu, Yunxiao ^a   Zheng, Wenli ^a   Yi, Yan ^a   Luo, Yunya ^a   Gong, Fanjie ^a   Peng, Honglin ^a   Pei, Minfei ^a   Deng, Mingyang ^a   Zhang, Guangsen ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MITOCHONDRIA; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; PROGNOSIS; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; YOUNG ADULT;

EID: 84894235091     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083610     Document Type: Article

References (47)

1. Löwenberg B, Downing J, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341: 1051-1062. (Pubitemid 29451802)
2. British Committee for Standards in Haematology, Milligan DW, Grimwade D, Cullis JO, Bond L, et al. (2006) Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 135: 450-474.
3. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, et al. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 115: 453-474.
4. Warburg O (1930) The metabolism of tumors. London: Constable CO Ltd.
5. Warburg O (1956) On the origin of cancer cells. Science 123: 309-314.
6. Pelicano H, Martin DS, Xu RH, Huang P (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25: 4633-4646. (Pubitemid 44187614)
7. Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482. (Pubitemid 351766797)
8. Cuezva JM, Ortega AD, Willers I, Sánchez-Cenizo L, Aldea M, et al. (2009) The tumor suppressor function of mitochondria: translation into the clinics. Biochim Biophys Acta 1792: 1145-1158.
9. Tennant DA, Durán RV, Gottlieb E (2010) Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10: 267-277.
10. Sánchez-Aragó M, Formentini L, Cuezva JM (2012) Mitochondria-Mediated Energy Adaption in Cancer: The H (+)-ATP Synthase-Geared Switch of Metabolism in Human Tumors. Antioxid Redox Signal; e-pub ahead of print 24 Sep 2012; doi:101089/ars20124883.
11. Formentini L, Martínez-Reyes I, Cuezva JM (2010) The Mitochondrial Bioenergetic Capacity of Carcinomas. IUBMB Life 62: 554-560.
12. Boyer PD (1997) The ATP synthase: A splendid molecular machine. Annu Rev Biochem 66: 717-749.
13. Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaría G, et al. (2002) The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 62: 6674-6681. (Pubitemid 35364137)
14. Sánchez-Aragó M, Chamorro M, Cuezva JM (2010) Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis 31: 567-576.
15. Aldea M, Clofent J, Núñez de Arenas C, Chamorro M, Velasco M, et al. (2011) Reverse phase protein microarrays quantify and validate the bioenergetic signature as biomarker in colorectal cancer. Cancer Letters 311: 210-218.
16. Isidoro A, Martinez M, Fernandez PL, Ortega AD, Santamaría G, et al. (2004) Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem J 378: 17-20. (Pubitemid 38299539)
17. Cuezva JM, Chen G, Alonso AM, Isidoro A, Misek DE, et al. (2004) The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis 25: 1157-1163. (Pubitemid 38968043)
18. López-Ríos F, Sánchez-Aragó M, García-García E, Ortega AD, Berrendero JR, et al. (2007) Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res 67: 9013-9017. (Pubitemid 47535883)
19. Isidoro A, Casado E, Redondo A, Acebo P, Espinosa E, et al. (2005) Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 26: 2095-2104. (Pubitemid 41672197)
20. Ortega AD, Sala S, Espinosa E, González-Barón M, Cuezva JM (2008) HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence. Carcinogenesis 29: 2053-2061.
21. Santamaría G, Martínez-Diez M, Fabregat I, Cuezva JM (2006) Efficient execution of cell death in non-glycolytic cells requires the generation of ROS controlled by the activity of mitochondrial Ht-ATP synthase. Carcinogenesis 27: 925-935.
22. Lin PC, Lin JK, Yang SH, Wang HS, Li AF,et al. (2008)Expression of beta-F1- ATPase and mitochondrial transcription factor A and the change in mitochondrial DNA content in colorectal cancer: clinical data analysis and evidence from an in vitro study. Int J Colorectal Dis 23: 1223-1232.
23. Shin YK, Yoo BC, Chang HJ, Jeon E, Hong SH, et al. (2005) Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 65: 3162-3170. (Pubitemid 40524597)
24. Hernlund E, Hjerpe E, Avall-Lundqvist E, Shoshan M (2009) Ovarian carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-glucose treatment. Mol Cancer Ther 8: 1916-1923.
25. Li RJ, Zhang GS, Chen YH, Zhu JF, Lu QJ, et al. (2010) Downregulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance. Ann Oncol 7: 1506-1514.
26. Arber DA, Brunning RD, Le Beau MM, Falini B (2008) Acute myeloid leukemia with recurrent genetic abnormalities: WHO classification of tumors of haematopoietic and lymphoid tissues.
27. Harris N, Jaffe E, Diebold J, Flandrin G, Muller-Hermelink H,et al. (1999) The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Ann Oncol 10: 1419-1432.
28. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, et al. (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21: 4642-4649. (Pubitemid 46594039)
29. Chevallier P, Labopin M, Turlure P, Prebet T, Pigneux A, et al. (2011) A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia 6: 939-944.
30. Oguri T, Fujiwara Y, Isobe T, Katoh O, Watanabe H, et al. (1998) Expression of gamma-glutamylcysteine synthetase (gamma-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs. Br J Cancer 77: 1089-1096.
31. Ortega AD, Cuezva JM (2005) New frontiers in mitochondrial biogenesis and disease, Research Signpost, Kerala, India, In Villarroya F. 111p-139p.
32. Wang X (2001) The expanding role of mitochondria in apoptosis. Genes Dev 15: 2922-2933.
33. Dey R, Moraes CT (2000) Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-x (L) in ost eosarcoma cells. J Bio Chem 275: 7087-7094. (Pubitemid 30146256)
34. Harris MH, Vander Heiden MG, Kron SJ, Thompson CB (2000) Role of oxidative phosphorylation in Bax toxicity. Mol Cell Biol 20: 3590-3596. (Pubitemid 30243904)
35. Matsuyama S, Xu Q, Velours J, Reed JC (1998) The Mitochondrial F0F1-ATPase proton pump is required for function of the proapoptotic protein Bax in yeast and mammalian cells. Mol Cell 1: 327-336. (Pubitemid 128378881)
36. Formentini L, Sanchez-Arago M, Sanchez-Cenizo L, Cuezva JM (2012) The mitochondrial ATPase inhibitory Factor 1(IF1) triggers a ROS-mediated retrograde pro-survival and proliferative response. Mol Cell 45: 731-742.
37. Sanchez-Cenizo L, Formentini L, Aldea M, Ortega AD, Garcia-Huerta P, et al. (2010) Upregulation of ATPase inhibitory factor 1(IF1) of the mitochondrial H+-ATP synthase in human tumous mediates the metabolic shift of cancer cells to a Warbugy phenotype. J Biol Chem 285: 25308-25313.
38. Willers IM, Cuezva JM (2011) Post-transcriptional regulation of the mitochondrial H+-ATP synthase:a key regulator of the metabolic phenotype in cancer. Biochim Biophys Acta 1807: 543-551.
39. Hernlund E, Ihrlund LS, Khan O, Ates YO, Linder S, et al. (2008) Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int J Cancer 123: 476-483. (Pubitemid 351842036)
40. Sánchez-Aragó M, Cuezva JM (2011) The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil.
41. Schulz TJ, Thierbach R, Voigt A, Drewes G, Mietzner B, et al. (2006) Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited. J Biol Chem 281: 977-981.
42. Green DR, Reed JC (1998) Mitochondria and apoptosis. Science 281: 1309-1312. (Pubitemid 28406816)
43. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, et al.(2011) Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 334: 1129-1133.
44. He SM, Li R, Kanwar JR, Zhou SF (2011) Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). Curr Med Chem 18: 439-481.
45. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, et al. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654. (Pubitemid 23012438)
46. Slapak CA, Fracasso PM, Martell RL, Toppmeyer DL, Lecerf JM, et al. (1994) Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells. Cancer Res 54: 5607-5613. (Pubitemid 24346255)
47. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, et al. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89: 3323-3329.